Overview

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

Status:
Terminated

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

This prospective, national, multicenter, observational study will evaluate in routine clinical practice the efficacy and safety of re-treatment with Pegasys (peginterferon alfa-2a) plus ribavirin or regimens containing direct-acting antivirals in participants with chronic hepatitis C who failed previous treatment. Participants will be followed for the duration of their treatment (24, 48 or 72 weeks) and for 24 weeks of follow-up.

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2a
Ribavirin